Real-world Evidence, Evidera, London, W6 8BJ, UK.
Health Economics & Outcomes Research, Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UB8 1DH, UK.
Future Oncol. 2021 Aug;17(24):3163-3174. doi: 10.2217/fon-2021-0199. Epub 2021 Jun 8.
This study provides real-world insight into patient profile, clinical effectiveness and health-related quality of life among patients with advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma treated with nivolumab. Data were collected from medical records of patients with advanced GEJ adenocarcinoma treated with nivolumab in a UK Early Access to Medicines Scheme and from the patient-reported EuroQoL five dimensions questionnaire. Evaluable patients (n = 113; median age 62 years) were predominantly male (76.1%), White (87.4%) and with GEJ adenocarcinoma (61.9%). Median follow-up was 2.8 months. The 6-month progression-free survival and overall survival were 31.6 and 56.7%, respectively. Mean EuroQoL five dimensions questionnaire index utility scores at baseline, 8, 16 and 24 weeks were 0.795, 0.831, 0.870 and 0.793, respectively. Progression-free survival was consistent with trial results and health-related quality of life remained stable over time.
本研究提供了真实世界的见解，了解接受纳武利尤单抗治疗的晚期胃/胃食管结合部（GEJ）腺癌患者的患者特征、临床疗效和健康相关生活质量。数据来自在英国早期药物准入计划中接受纳武利尤单抗治疗的晚期 GEJ 腺癌患者的病历和患者报告的 EuroQoL 五维问卷。可评估患者（n=113；中位年龄 62 岁）主要为男性（76.1%）、白人（87.4%）和 GEJ 腺癌（61.9%）。中位随访时间为 2.8 个月。6 个月无进展生存率和总生存率分别为 31.6%和 56.7%。基线时、8 周、16 周和 24 周时的平均 EuroQoL 五维问卷指数效用评分分别为 0.795、0.831、0.870 和 0.793。无进展生存率与试验结果一致，健康相关生活质量随时间保持稳定。
